“Deborah agreed to take part in a trial as she was keen to help other cancer patients in the future. "If taking part in a trial means others might be helped then I’m very happy with that."
A trial looking at LCL161 and paclitaxel before surgery for triple negative breast cancer
We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.
This trial looked at LCL161 with paclitaxel for breast cancer that doesn’t have receptors for progesterone, oestrogen or HER2. This is called triple negative breast cancer.
More about this trial
- how well LCL161 with paclitaxel works for triple negative breast cancer
- more about the side effects
Summary of results
- 103 women had paclitaxel
- 106 women had paclitaxel and LCL161
- 17 out of 103 women (17%) who had paclitaxel
- 17 out of 106 women (16%) who had paclitaxel and LCL161
- less than 2 out of 10 women (17%) who had paclitaxel
- nearly 4 out of 10 women (38%) who had paclitaxel and LCL161
- less than 2 out of 10 women (16%) who had paclitaxel
- less than 1 out of 10 women (6%) who had paclitaxel and LCL161
- extreme tiredness (fatigue)
- a drop in white blood cells
How to join a clinical trial
Professor Peter Schmid
Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer